Elite Pharmaceuticals ( (ELTP) ) has shared an announcement.
On April 30, 2025, Elite Pharmaceuticals announced the launch of its generic version of Percocet® (oxycodone hydrochloride and acetaminophen tablets) in various dosages. This product targets the market for moderate to moderately severe pain relief, with 2024 annual sales reported at approximately $317 million. The launch is expected to enhance Elite’s market presence in the niche generic pharmaceutical sector.
Spark’s Take on ELTP Stock
According to Spark, TipRanks’ AI Analyst, ELTP is a Neutral.
Elite Pharmaceuticals faces significant profitability challenges, as reflected by its negative net income and EBITDA. The stock’s bearish technical indicators and negative valuation metrics further emphasize the company’s financial difficulties. On a positive note, the company exhibits low financial leverage and has expanded its operational capabilities, which may support future growth. However, the recent revenue and profit declines highlight ongoing operational challenges. Overall, the stock score reflects a cautious outlook.
To see Spark’s full report on ELTP stock, click here.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. The company’s product lines include immediate-release and controlled-release solid oral dose products, marketed under the Elite Laboratories label and through licenses to third-party organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing in Northvale, NJ.
YTD Price Performance: -24.73%
Average Trading Volume: 915,992
Technical Sentiment Signal: Sell
Current Market Cap: $443.1M
For an in-depth examination of ELTP stock, go to TipRanks’ Stock Analysis page.